XELJANZ (tofacitinib citrate)

06:08 EST 16th December 2018 | BioPortfolio

XELJANZ is a prescription medicine called a Janus kinase (JAK) inhibitor. XELJANZ is used to treat adults with moderately to severely active rheumatoid arthritis in which methotrexate did not work well.

  • It is not known if XELJANZ is safe and effective in people with Hepatitis B or C.
  • XELJANZ is not for people with severe liver problems.
  • It is not known if XELJANZ is safe and effective in children.

First in a new class of treatments. Another way to treat RA.
XELJANZ is a JAK inhibitor.
JAK inhibitors work deep within the cells to interfere with the cellular activities that have been linked to the inflammation associated with RA.
XELJANZ works from the inside out.
The inflammation of RA involves steps that occur inside and outside of the cell. XELJANZ works deep inside the cell.
XELJANZ is a small pill taken twice a day.
XELJANZ is a prescription medication that’s dispensed in pill form. It is a small molecule that can be taken orally.
XELJANZ can be taken without methotrexate.

In clinical studies of more than 3,000 patients, some patients taking XELJANZ experienced a reduction in joint pain and swelling within 2 weeks. For some others it took 3-6 months. However, every patient is different, so your results may vary.


Quick Search


review and buy XELJANZ (tofacitinib citrate) market research data and corporate reports here